Cargando…

EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab

Detalles Bibliográficos
Autores principales:	van de Langerijt, B., Doorduijn, J. K., Lam, K. H., van den Bent, M. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090574/ https://www.ncbi.nlm.nih.gov/pubmed/21136270 http://dx.doi.org/10.1007/s00415-010-5854-3

Ejemplares similares

EBV-Related Diffuse Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma
por: Şimşek, Cem, et al.
Publicado: (2019)

Acute painful lumbosacral paresthesia after intrathecal rituximab
por: Bromberg, J. E. C., et al.
Publicado: (2011)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Mycobacterium haemophilum Infection after Alemtuzumab Treatment
por: Kamboj, Mini, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
por: Karlsson, C, et al.
Publicado: (2011)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type
por: Rosenfeldt, Mathias T., et al.
Publicado: (2020)

Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis
por: Metz, Imke, et al.
Publicado: (2016)

Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia
por: Ronchetti, Anne-Marie, et al.
Publicado: (2014)

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
por: van der Meulen, Matthijs, et al.
Publicado: (2020)

EBV-positive diffuse large B-cell lymphoma of the elderly with aberrant expression of CD3 and TIA-1
por: Lee, Miji, et al.
Publicado: (2013)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

EBV and HIV-Related Lymphoma
por: Bibas, Michele, et al.
Publicado: (2009)

Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia
por: Meeuse, Jan J., et al.
Publicado: (2007)

Therapy-related Acute Myeloid Leukemia Following Treatment for Burkitt's Lymphoma
por: Lee, Seung-Shin
Publicado: (2017)

Comment on “Alemtuzumab improves cognitive processing speed in active multiple sclerosis – a longitudinal observational study”
por: Asadollahzade, Elnaz, et al.
Publicado: (2022)

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

Genetic susceptibility to therapy-related leukemia after Hodgkin lymphoma or non-Hodgkin lymphoma: role of drug metabolism, apoptosis and DNA repair
por: Ding, Y, et al.
Publicado: (2012)

SARS-CoV-2 and EBV coinfection()
por: García-Martínez, Francisco Javier, et al.
Publicado: (2020)

Base-pair resolution DNA methylome of the EBV-positive Endemic Burkitt lymphoma cell line DAUDI determined by SOLiD bisulfite-sequencing
por: Kreck, B, et al.
Publicado: (2013)

EBV & lymphoma
por: Caballero, Dolores
Publicado: (2019)

Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA
por: Liang, J-H, et al.
Publicado: (2017)

Transformation of follicular lymphoma to high-grade Burkitt's like lymphoma and acute lymphoblastic leukemia-L3 type
por: Majhi, Urmila, et al.
Publicado: (2013)

Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma
por: Ratner, L, et al.
Publicado: (2016)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Treatment and Survival of Patients With Primary Effusion Lymphoma in the Netherlands: A Population-based Analysis, 2002–2015
por: Dinmohamed, Avinash G., et al.
Publicado: (2018)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma
por: van der Meulen, Matthijs, et al.
Publicado: (2021)

Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia
por: Vargova, J, et al.
Publicado: (2016)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas
por: Mundo, Lucia, et al.
Publicado: (2020)

A case of adult T-cell leukemia/lymphoma in Korea
por: Lee, Yong-Moon, et al.
Publicado: (2018)

EBV in Hodgkin Lymphoma
por: Massini, Giuseppina, et al.
Publicado: (2009)

Flow cytometry shows added value in diagnosing lymphoma in brain biopsies
por: van der Meulen, Matthijs, et al.
Publicado: (2018)

Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis
por: Kuhlman, Justin J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_je1179m3722rj59fifmmnaf379